LOS ANGELES, July 7, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, has announced the availability of a new Q&A interview with Dr. Enrico Girardi, one of the foremost soldiers in the global fight to defeat malaria. Dr. Girardi discussed efforts by Xenomics Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, to develop significant new solutions to help fight the deadly disease malaria.
President Bush recently urged a major new initiative to aid Africa, which included $1.2 billion specifically to help reduce the toll of malaria. President Bush outlined his proposals in an address June 30, 2005, the text of which can be read on this site. Malaria threatens hundreds of millions of people in Africa and worldwide, and kills millions each year, the majority of them children under five.
"The toll of malaria is even more tragic because the disease, itself, is highly treatable and preventable, President Bush said. "Yet this is also our opportunity, because we know that large-scale action can defeat this disease in whole regions." The full text of the President's speech can be read on the BiomedDiscoveries.com website.
Dr. Girardi conducts pioneering clinical research at the National Institute for Infectious Diseases in Rome, Italy, where he works with Xenomics to help develop new diagnostic tests to detect malaria and assist in its treatment. Xenomics groundbreaking non-invasive medical diagnostic technology is based on the detection of Transrenal-DNA (Tr-DNA), particles of genetic material that are eliminated in the urine. Xenomics is developing medical tests that use Tr-DNA to diagnose a range of diseases and genetic conditions, with uniquely high degrees of accuracy, and at very early stages.
"The problem is malaria is far more effectively treated and cured at the first stage of infection, yet there is no early-stage diagnostic test currently available on the market," Dr. Girardi said. "So, Xenomics is developing a tool for accurate detection at an early stage of the infection, so that the disease can be effectively treated."
To read the interview, please visit http://www.BiomedDiscoveries.com.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com.
Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Xenomics of $10,000 per month through January 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. The Company issued Trilogy warrants to purchase 1,000,000 shares of Common Stock of the Company at an exercise price of $2.95 per share (the "Warrants"). The Warrants issued to Trilogy are exercisable upon issuance and expire on January 10, 2008. In the event the Company proposes to register any of its Common Stock under the Securities Act of 1933 for sale in connection with a public offering of Common Stock, the Company will give written notice to Trilogy and will include in such registration statement any of the shares of Common Stock underlying the Warrants which Trilogy may request be included. The offer and sale of these securities was made in reliance on Section 4(2) of the Securities Act of 1933, as amended. The offer and sale of the Warrants did not involve a public offering.